Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Medartis 2023 half-year results presentation – Biotech Investments

Medartis Holding AG / Key word(s): Half Year Results Medartis 2023 half-year results presentation 25.07.2023 / 09:00 CET/CEST INVITATION │ AUDIO WEBCAST We are pleased

July 26, 2023

Quidelortho sees highest filings and grants during October in Q4 2023

Share this article Quidelortho has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q4 2023 The European Patent Office(EPO) Patent

February 27, 2024

Researchers discover brain pathways involved in sleep preparatory behavior in mice

Researchers have discovered the brain pathways involved in ‘sleep preparatory behaviour’ in mice, which is likely to also apply to humans.

September 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.